<--- Back to Details
First PageDocument Content
Viral vector / Retrovirus / Vector / Gene therapy / HEK cell / Lentivirus / Vesicular stomatitis virus / Feline immunodeficiency virus / Murine leukemia virus / Biology / Molecular biology / Gene delivery
Viral vector
Retrovirus
Vector
Gene therapy
HEK cell
Lentivirus
Vesicular stomatitis virus
Feline immunodeficiency virus
Murine leukemia virus
Biology
Molecular biology
Gene delivery

Briefing Document — Testing for Replication Competent Retrovirus (RCR)/Lentivirus (RCL) in Retroviral and Lentiviral Vector Based Gene Therapy Products — Revisiting Current FDA Recommendations

Add to Reading List

Source URL: www.fda.gov

Download Document from Source Website

File Size: 127,66 KB

Share Document on Facebook

Similar Documents

Cancer Gene Therapy, 587–597 r 2011 Nature America, Inc. All rights reservedwww.nature.com/cgt

Cancer Gene Therapy, 587–597 r 2011 Nature America, Inc. All rights reservedwww.nature.com/cgt

DocID: 1vllG - View Document

Washington University in St. Louis Institutional Biological & Chemical Safety Committee Policy on Severe Adverse Event Reporting for Human Gene Therapy Trials As outlined in Section IV-B-2-b-(1) of the NIH Guidelines for

Washington University in St. Louis Institutional Biological & Chemical Safety Committee Policy on Severe Adverse Event Reporting for Human Gene Therapy Trials As outlined in Section IV-B-2-b-(1) of the NIH Guidelines for

DocID: 1vily - View Document

RARE TOOLKITS ™  A Guide to Gene Therapy Table of Contents Intro to Gene Therapy: Gene Pool

RARE TOOLKITS ™ A Guide to Gene Therapy Table of Contents Intro to Gene Therapy: Gene Pool

DocID: 1v306 - View Document

Pioneering the Development of Safe and Effective Non-Viral Vectors and Processes for Human Gene Therapy and DNA Vaccination. Founded 1999, Clague Hodgson, Ph.D. Chief Scientific Officer, VP, R&D, Jim Williams, Ph.D. (200

Pioneering the Development of Safe and Effective Non-Viral Vectors and Processes for Human Gene Therapy and DNA Vaccination. Founded 1999, Clague Hodgson, Ph.D. Chief Scientific Officer, VP, R&D, Jim Williams, Ph.D. (200

DocID: 1uuzW - View Document

Emily Abrash Final Paper 16 March 2012 Stem Cell Gene Therapy as a Treatment for Diverse Genetic Disorders Mendelian genetic disorders are diverse in their pathophysiology, symptoms, and prognosis, yet have in common the

Emily Abrash Final Paper 16 March 2012 Stem Cell Gene Therapy as a Treatment for Diverse Genetic Disorders Mendelian genetic disorders are diverse in their pathophysiology, symptoms, and prognosis, yet have in common the

DocID: 1uni0 - View Document